Analysts Set Vivos Therapeutics, Inc. (NASDAQ:VVOS) PT at $4.92

Shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) have earned an average recommendation of “Hold” from the five ratings firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have given a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $4.9167.

VVOS has been the topic of a number of recent research reports. Ascendiant Capital Markets decreased their target price on Vivos Therapeutics from $6.50 to $5.50 and set a “buy” rating on the stock in a report on Wednesday, December 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Vivos Therapeutics in a report on Wednesday, January 21st. HC Wainwright began coverage on Vivos Therapeutics in a research report on Monday, November 17th. They set a “buy” rating and a $7.00 target price for the company. Finally, Zacks Research upgraded Vivos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, December 1st.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Connective Capital Management LLC purchased a new stake in Vivos Therapeutics in the third quarter worth $620,000. DRW Securities LLC boosted its holdings in shares of Vivos Therapeutics by 179.5% in the 4th quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after buying an additional 74,441 shares in the last quarter. B. Riley Wealth Advisors Inc. purchased a new position in Vivos Therapeutics in the second quarter worth $220,000. XTX Topco Ltd purchased a new position in Vivos Therapeutics during the 2nd quarter worth $65,000. Finally, Acorn Wealth Advisors LLC acquired a new position in shares of Vivos Therapeutics during the fourth quarter valued at about $30,000. Institutional investors own 26.35% of the company’s stock.

Vivos Therapeutics Trading Down 4.3%

Vivos Therapeutics stock opened at $1.35 on Wednesday. Vivos Therapeutics has a 52-week low of $1.32 and a 52-week high of $7.95. The company has a market cap of $14.13 million, a P/E ratio of -0.76 and a beta of 6.94. The company has a quick ratio of 0.78, a current ratio of 0.78 and a debt-to-equity ratio of 3.31. The business has a 50-day simple moving average of $1.81 and a two-hundred day simple moving average of $2.57.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.